Treatments

We have some exciting news for people living with pancreatitis caused by the FCS genetic mutation. On November 18, 2025, the FDA has approved REDEMPLO® (plozasiran), a new treatment from Arrowhead Pharmaceuticals that lowers triglycerides and reduces acute pancreatitis attacks in adults with Familial Chylomicronemia Syndrome (FCS). This is an important step for people with

High triglycerides are one of the leading causes of pancreatitis, and for some people, extremely high levels can be caused by a rare genetic condition called Familial Chylomicronemia Syndrome (FCS). We’re excited to share a new resource created for and by the FCS community in partnership with Arrowhead Pharmaceuticals. This was specifically designed for people

Exciting news! On December 19, 2024, the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA (olezarsen), developed by Ionis, as the first-ever treatment for Familial Chylomicronemia Syndrome (FCS). FCS is a rare genetic condition that causes dangerously high triglyceride levels, increasing the risk of severe health complications–especially pancreatitis. This approval is a major milestone—not